Table 2.
Relationship between clinic-histopathological factors with Ki-67, p53 and BCL-2 biomarkers.
| All (n = 76) | Ki-67a No. (%) |
p53b No. (%) |
BCL-2c No. (%) |
Fisher’s Exact test p-value | |
|---|---|---|---|---|---|
| Age (years)* | 51.32 ± 14.28 | 50.2 ± 14.0 | 54.1 ± 16.8 | 51.0 ± 12.5 | 0.167a |
| 0.428b | |||||
| 0.411c | |||||
| T stage | |||||
| T1 | 6 (8.10%) | 3 (4.7%) | 1 (3.4%) | 3 (4.05%) | 0.078a |
| T2 | 14 (18.91%) | 12 (18.8%) | 1 (3.4%) | 9 (12.15%) | 0.007 b |
| T3 | 18 (24.32%) | 16 (25.0%) | 7 (24.1%) | 8 (10.80%) | 0.419c |
| T4 | 36 (48.64%) | 33 (51.5%) | 20 (69.0%) | 24 (32.42%) | |
| Nodule status | |||||
| N0 | 13 (17.6%) | 11 (17.2%) | 3 (10.3%) | 8 (18.2%) | |
| N1 | 10 (13.5%) | 8 (12.5%) | 3 (10.3%) | 7(15.9%) | 0.338a |
| N2 | 30 (40.5%) | 28 (43.8%) | 15 (51.7%) | 17 (38.6%) | 0.209b |
| N3 | 15 (20.3%) | 13 (20.3%) | 4 (10.3%) | 8 (18.2%) | 0.939c |
| Nx | 6 (7.4%) | 4 (6.3%) | 4 (10.3%) | 4 (9.1%) | |
| Grade | |||||
| Grade 1 | 12 (16.4%) | 8 (12.5%) | 3 (10.4%) | 7 (16.7%) | 0.054 a |
| Grade 2 | 36 (49.3%) | 32 (50.0%) | 15 (51.7%) | 20 (47.6%) | 0.560b |
| Grade 3 | 25 (34.2%) | 24 (37.5%) | 11 (37.9%) | 15 (35.7%) | 0.949c |
| Cancer stage | |||||
| Stage I | 3 (4.1%) | 2 (3.1%) | 0 (0%) | 2 (4.5%) | |
| Stage II | 7 (9.5%) | 5 (7.8%) | 1 (3.4%) | 3 (6.8%) | 0.217a |
| Stage III | 36 (48.6%) | 33 (51.6%) | 13 (44.8%) | 23 (52.3%) | 0.121b |
| Stage IV | 28 (37.8%) | 24 (37.5%) | 15 (51.7%) | 16 (36.4%) | 0.758c |
| Histologic subtype | |||||
| IDC | 66 (86.8%) | 57 (87.7%) | 29 (96.7%) | 38 (86.4%) | 0.345 |
| ILC | 5 (6.6%) | 4 (6.2%) | 1 (3.3%) | 4 (9.1%) | 0.595 |
| MC | 1 (1.3%) | 1 (1.5%) | 0 (0%) | 1 (2.3%) | 0.361 |
| MucC | 1 (1.3%) | 1 (1.5%) | 0 (0%) | 1 (2.3%) | |
| Others | 3 (3.9%) | 2 (3.0%) | 0 (0%) | 0 (0%) | |
a,b,cIs p-value from the Fisher’s exact test.
*Mean ± SD.